BANGKOK, Feb. 28, 2025 — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), an Asian fertility services provider assisting individuals and couples in accessing fertility treatments, announced today the receipt of a Compliance Notice dated February 27, 2025, from Nasdaq confirming the Company’s compliance with Nasdaq Listing Rule 5450(a)(1), the Minimum Bid Price Requirement.
As previously disclosed, Nasdaq notified the Company on October 8, 2024, that it was not compliant with the Minimum Bid Price Requirement because the closing bid price of its Class A Ordinary Shares (“Ordinary Shares”) had remained below $1.00 per share for 30 consecutive business days. The Compliance Notice indicates that NewGen has regained compliance, as the closing bid price of its Ordinary Shares was $1.00 or higher for 10 consecutive business days, spanning from February 11, 2025, to February 26, 2025. The matter is now considered closed.
The Company also received a Transfer Notice dated February 27, 2025, from Nasdaq, stating that the company’s application to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market has been approved. The Ordinary Shares and publicly traded warrants will continue to be traded under the symbols “NIVF” and “NIVFW,” respectively. The company anticipates that the transfer to the Nasdaq Capital Market will not affect the trading of its securities. The transfer is scheduled to take effect at the start of trading on February 28, 2025.
About NewGen
NewGen is a comprehensive fertility services provider in Asia, dedicated to helping couples and individuals access fertility treatments. With a mission to help individuals and couples build families regardless of fertility challenges, NewGen is committed to expanding access to infertility treatment and providing comprehensive fertility services. The management team at NewGen collectively has over a decade of experience in the fertility industry. NewGen operates clinics in Thailand, Cambodia, and Kyrgyzstan, offering a complete range of services, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, where permitted by local laws. For more information, please visit . Information found on NewGen’s website is not incorporated by reference into this press release and should not be considered a part of it.
Forward-Looking Statements
This press release includes forward-looking statements made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are generally identified by terms such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, these statements include descriptions of the Company’s future commercial operations, business strategy, and financial condition. These forward-looking statements are predictions, projections, and other statements about future events based on current expectations and assumptions and are therefore subject to risks and uncertainties. Numerous factors could cause actual future events to differ materially from those described in the forward-looking statements. Readers should carefully consider these factors, as well as the other risks and uncertainties detailed in the Company’s annual report on Form 20-F and other documents filed or to be filed with the SEC, which may cause actual events and results to differ significantly from those projected in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided is current as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required by law.
Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email:
“`